• Diffuse Large B Cell Lymphoma
• Hodgkin's Lymphoma
• Non-Hodgkin's Lymphoma

The focus of my research has been on examining disparities in lymphoma survival to identify opportunities to design and implement rational clinical trials aimed at improving outcomes for high-risk patients. I have completed analyses using large databases in follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) identifying characteristics that predict for inferior outcomes. My early efforts in this arena identified disparities in the use of potentially-curative, chemo-immunotherapy in the treatment of DLBCL patients. This study demonstrated that race and insurance status were associated with significant differences in the administration of chemo-immunotherapy among US patients with DLBCL.